A new benzodiazepine pharmacology.

doi:10.1124/JPET.300.1.2

Paper

A new benzodiazepine pharmacology.

Published 2002 · H. Möhler, J. Fritschy, U. Rudolph

The Journal of pharmacology and experimental therapeutics

Q2 SJR score

696

Citations

42

Influential Citations

Full textSemantic Scholar

Abstract

Classical benzodiazepine drugs are in wide clinical use as anxiolytics, hypnotics, anticonvulsants, and muscle relaxants. They act by enhancing the gamma-aminobutyric acid(A) (GABA(A)) receptor function in the central nervous system. The pharmacological relevance of the multitude of structurally diverse GABA(A) receptor subtypes has only recently been identified. Based on an in vivo point mutation strategy, alpha(1)-GABA(A) receptors were found to mediate sedation, anterograde amnesia, and part of the seizure protection, whereas alpha(2)-GABA(A) receptors, but not alpha(3)-receptors, mediate anxiolysis. Rational drug targeting to specific receptor subtypes has now become possible. Only restricted neuronal networks will be modulated by the new subtype-selective drugs. Promising new anxiolytics have already been developed. A new pharmacology of the benzodiazepine site is on the horizon.

Highly Cited

Study Snapshot

New benzodiazepine drugs targeting specific receptor subtypes offer potential for targeted neuronal modulation, offering new anxiolytics and sedation treatments.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

A new benzodiazepine pharmacology.

Sign up to use Study Snapshot

References

Citations